tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
FibroGen’s Strategic Moves and Financial Outlook: Hold Rating Amid Uncertainties
PremiumRatingsFibroGen’s Strategic Moves and Financial Outlook: Hold Rating Amid Uncertainties
3M ago
FibroGen’s Strategic Moves and Financial Highlights
Premium
Company Announcements
FibroGen’s Strategic Moves and Financial Highlights
3M ago
FibroGen reports Q3 EPS ($3.25), consensus ($4.01)
Premium
The Fly
FibroGen reports Q3 EPS ($3.25), consensus ($4.01)
3M ago
FibroGen initiates Phase 2 trial of FG-3246
PremiumThe FlyFibroGen initiates Phase 2 trial of FG-3246
5M ago
SEC charges former FibroGen CMO for false claims on clinical trial results
Premium
The Fly
SEC charges former FibroGen CMO for false claims on clinical trial results
5M ago
FibroGen Sells Subsidiary to AstraZeneca for $220 Million
Premium
Company Announcements
FibroGen Sells Subsidiary to AstraZeneca for $220 Million
5M ago
FibroGen Gains Approval for Subsidiary Sale to AstraZeneca
PremiumCompany AnnouncementsFibroGen Gains Approval for Subsidiary Sale to AstraZeneca
6M ago
FibroGen announces approval for FibroGen China sale to AstraZeneca
Premium
The Fly
FibroGen announces approval for FibroGen China sale to AstraZeneca
6M ago
FibroGen Amends Financing Agreement with Morgan Stanley
Premium
Company Announcements
FibroGen Amends Financing Agreement with Morgan Stanley
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100